Vivus has amended its manufacturing and supply agreement with Nordmark Arzneimittel for Pancreaze (pancrelipase) delayed-release capsules covering an initial term of ten years.
The agreement may later be renewed for an additional five-year period.
Vivus CEO John Amos said: “As Vivus continues its ten-quarter turnaround, ensuring Pancreaze supply to meet the current and future demand for Pancreaze at a stable and predictable price was a key step in our strategy, and we are pleased to have achieved this important milestone.
“We believe that there is a significant opportunity to grow the Pancreaze market with our current product formulations and expect to create additional clinical and commercial value with the future introduction of advanced formulations of the product.”
Under the agreement, the companies will develop an advanced formulation of Pancreaze to extend the product’s shelf life. This variant is expected to be available in 2021.
Nordmark CEO Jörn Tonne said: “Nordmark has established expertise in manufacturing Pancreaze delayed-release capsules, and we are pleased to extend our agreement with Vivus for at least another ten years.
“We have a track record of success in developing new products and are committed to meeting the needs of our customers and the patients they serve.”
Nordmark and Vivus will work together to develop other formulations of Pancreaze that make treatment more convenient for patients with exocrine pancreatic insufficiency.
The companies have not disclosed the financial details of the agreement.
The prescription medicine Pancreaze is used to treat people whose pancreas does not make enough enzymes due to cystic fibrosis or other conditions.